← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Rockland Immunochemicals, Inc.
Pottstown, PA
$3,327,573
Total funding
10
Grants
Funding over time
peak $1.1M · FY2009–16$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$3,327,573 · 10
By mechanism
N43$1,299,327 · 6
R43$1,029,244 · 3
N44$999,002 · 1
Investigators at Rockland Immunochemicals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
SBIR TOPIC 229, PHASE II: PHARMACODYNAMIC ASSAY FOR AKT FOR USE WITH PI3K/AKT/MT$999,002
N44 · FY2011 · CA
Novel Point-of-Care Multiplex Lyme Disease Test$315,172
R43 · FY2009 · AI
TAS::75 0849::TAS THE CONTRACTOR WILL UTILIZE THE MAMMALIAN EXPRESSION SYSTEM ($299,954
N43 · FY2010 · CA
IGF::OT::IGF SYSTEMIC PRE-TARGETED RADIOIMMUNOTHERAPY WITH BISPECIFIC NANOBODIES FOR CANCER TREATMENT$299,625
N43 · FY2016 · CA
TOPIC 324 PHASE I 9 MONTH FUNDING; NOVEL IMAGING AGENTS T EXPAND TE CLINICAL TOOL$249,975
N43 · FY2013 · CA
Synthetic antibodies for monitoring modified RNAs$225,000
R43 · FY2014 · DA
Antibody-based Point-of-Care Device for the Diagnosis of Sickle Cell Disease$224,635
R43 · FY2015 · HL
Antibody-based Point-of-Care Device for the Diagnosis of Sickle Cell Disease$224,437
R43 · FY2014 · HL
Development of Molecular Pharmacodynamic Assays for Targeted Therapies$149,970
N43 · FY2009 · CA
TAS::75 0849::TAS MULTIPLEXED ASSAYS FOR AKT/M TOR PATHWAY - PHASE I SBIR TOPIC$149,937
N43 · FY2010 · CA
TAS::75 0849::TAS SBIR TOPIC 292 PHASE I DEVELOPMENT OF MOLECULAR PHARMACODYNAMI$149,866
N43 · FY2011 · CA
Developing a Point-of-Care Device for the Diagnosis of Sickle Cell Disease in Low Resource Settings$40,000
R43 · FY2016 · HL